$VERA
Vera Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024094108 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.487M $8.032M
YoY Change 67.61% 39.95%
% of Gross Profit
Research & Development $40.31M $29.31M
YoY Change 150.4% 80.59%
% of Gross Profit
Depreciation & Amortization $24.00K $26.00K
YoY Change
% of Gross Profit
Operating Expenses $49.80M $37.34M
YoY Change 128.91% 69.97%
Operating Profit -$49.80M -$37.34M
YoY Change 128.91% 69.97%
Interest Expense $2.825M $1.912M
YoY Change 199.58% 109.19%
% of Operating Profit
Other Income/Expense, Net $3.169M $3.635M
YoY Change 91.83% 101.05%
Pretax Income -$46.63M -$33.71M
YoY Change 132.0% 67.19%
Income Tax
% Of Pretax Income
Net Earnings -$46.63M -$33.71M
YoY Change 131.95% 67.19%
Net Earnings / Revenue
Basic Earnings Per Share -$0.85 -$0.62
Diluted Earnings Per Share -$0.85 -$0.62
COMMON SHARES
Basic Shares Outstanding 54.83M 54.70M
Diluted Shares Outstanding 54.90M 54.73M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $353.3M $384.4M
YoY Change 120.96% 112.34%
Cash & Equivalents $27.26M $25.09M
Short-Term Investments $326.1M $359.3M
Other Short-Term Assets $1.129M $429.0K
YoY Change -41.26% -69.34%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $364.1M $394.7M
YoY Change 112.17% 107.09%
LONG-TERM ASSETS
Property, Plant & Equipment $368.0K $155.0K
YoY Change 982.35% 287.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $140.0K $460.0K
YoY Change -72.0% -1.08%
Total Long-Term Assets $4.429M $2.544M
YoY Change 10.78% -44.26%
TOTAL ASSETS
Total Short-Term Assets $364.1M $394.7M
Total Long-Term Assets $4.429M $2.544M
Total Assets $368.6M $397.3M
YoY Change 109.86% 103.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.602M $4.664M
YoY Change -62.59% -64.88%
Accrued Expenses $19.99M $11.64M
YoY Change 103.92% 5.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.46M $18.42M
YoY Change 7.49% -31.37%
LONG-TERM LIABILITIES
Long-Term Debt $50.47M $50.26M
YoY Change 101.88% 101.36%
Other Long-Term Liabilities $2.568M $741.0K
YoY Change 16.73% -74.07%
Total Long-Term Liabilities $53.04M $51.00M
YoY Change 94.99% 83.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.46M $18.42M
Total Long-Term Liabilities $53.04M $51.00M
Total Liabilities $79.50M $69.42M
YoY Change 53.15% 27.02%
SHAREHOLDERS EQUITY
Retained Earnings -$417.8M -$371.2M
YoY Change 47.42% 40.98%
Common Stock $705.8M $699.5M
YoY Change 73.35% 73.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $289.1M $327.9M
YoY Change
Total Liabilities & Shareholders Equity $368.6M $397.3M
YoY Change 109.86% 103.55%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$46.63M -$33.71M
YoY Change 131.95% 67.19%
Depreciation, Depletion And Amortization $24.00K $26.00K
YoY Change
Cash From Operating Activities -$36.89M -$24.78M
YoY Change 60.51% 39.44%
INVESTING ACTIVITIES
Capital Expenditures $238.0K $89.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $38.56M -$22.59M
YoY Change 137.55% -73.87%
Cash From Investing Activities $38.32M -$22.68M
YoY Change 136.09% -73.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 739.0K 3.439M
YoY Change 154.83% 696.06%
NET CHANGE
Cash From Operating Activities -36.89M -24.78M
Cash From Investing Activities 38.32M -22.68M
Cash From Financing Activities 739.0K 3.439M
Net Change In Cash 2.171M -44.02M
YoY Change -133.61% -57.59%
FREE CASH FLOW
Cash From Operating Activities -$36.89M -$24.78M
Capital Expenditures $238.0K $89.00K
Free Cash Flow -$37.12M -$24.87M
YoY Change 61.54% 39.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001831828
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40407
dei Entity Registrant Name
EntityRegistrantName
Vera Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-2744449
dei Entity Address Address Line1
EntityAddressAddressLine1
8000 Marina Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 120
dei Entity Address City Or Town
EntityAddressCityOrTown
Brisbane
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94005
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
770-0077
dei Security12b Title
Security12bTitle
Class A common stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
VERA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54827665
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25085000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45681000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
359302000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
115035000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10360000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11307000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
394747000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
172023000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
155000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1929000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2949000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
460000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
482000
CY2024Q2 us-gaap Assets
Assets
397291000
CY2023Q4 us-gaap Assets
Assets
175546000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4664000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11118000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2116000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2436000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11638000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8749000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
18418000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22303000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
50263000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
49877000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
455000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1395000
CY2024Q2 vera Accrued Liabilities And Other Liabilities Non Current
AccruedLiabilitiesAndOtherLiabilitiesNonCurrent
286000
CY2023Q4 vera Accrued Liabilities And Other Liabilities Non Current
AccruedLiabilitiesAndOtherLiabilitiesNonCurrent
286000
CY2024Q2 us-gaap Liabilities
Liabilities
69422000
CY2023Q4 us-gaap Liabilities
Liabilities
73861000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
55000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
44000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
699457000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
410492000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-450000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
251000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-371193000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-309102000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
327869000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
101685000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
397291000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
175546000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29311000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16231000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52511000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41340000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8032000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5739000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15944000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11887000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
37343000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
21970000
us-gaap Operating Expenses
OperatingExpenses
68455000
us-gaap Operating Expenses
OperatingExpenses
53227000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-37343000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21970000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68455000
us-gaap Operating Income Loss
OperatingIncomeLoss
-53227000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5104000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2239000
us-gaap Investment Income Interest
InvestmentIncomeInterest
9290000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3862000
CY2024Q2 us-gaap Interest Expense
InterestExpense
1912000
CY2023Q2 us-gaap Interest Expense
InterestExpense
914000
us-gaap Interest Expense
InterestExpense
3819000
us-gaap Interest Expense
InterestExpense
1789000
CY2024Q2 us-gaap Other Income
OtherIncome
450000
CY2023Q2 us-gaap Other Income
OtherIncome
511000
us-gaap Other Income
OtherIncome
904000
us-gaap Other Income
OtherIncome
953000
CY2024Q2 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-7000
CY2023Q2 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-28000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-11000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-30000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3635000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1808000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6364000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2996000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-33708000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20162000
us-gaap Net Income Loss
NetIncomeLoss
-62091000
us-gaap Net Income Loss
NetIncomeLoss
-50231000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-277000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-138000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-700000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
82000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-33985000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-20300000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-62791000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-50149000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54728552
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54728552
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44269772
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44269772
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52850242
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52850242
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40986907
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40986907
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
101685000
CY2024Q1 vera Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs
IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
269592000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6613000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
298000
CY2024Q1 vera Proceeds From Short Swing Settlement
ProceedsFromShortSwingSettlement
37000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4124000
CY2024Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-424000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-28383000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
353542000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3439000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4873000
CY2024Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-277000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-33708000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
327869000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
76908000
CY2023Q1 vera Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs
IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
107743000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
65000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
175000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2667000
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
220000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30069000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
157709000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
432000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2682000
CY2023Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-138000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20162000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
140523000
us-gaap Net Income Loss
NetIncomeLoss
-62091000
us-gaap Net Income Loss
NetIncomeLoss
-50231000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11000
vera Accretion Of Discount On Purchase Of Debt Securities Net
AccretionOfDiscountOnPurchaseOfDebtSecuritiesNet
-4475000
vera Accretion Of Discount On Purchase Of Debt Securities Net
AccretionOfDiscountOnPurchaseOfDebtSecuritiesNet
-1641000
vera Accretion Of Loan Exit Fee And Amortization Of Loan Costs
AccretionOfLoanExitFeeAndAmortizationOfLoanCosts
386000
vera Accretion Of Loan Exit Fee And Amortization Of Loan Costs
AccretionOfLoanExitFeeAndAmortizationOfLoanCosts
153000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1020000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1143000
us-gaap Share Based Compensation
ShareBasedCompensation
8997000
us-gaap Share Based Compensation
ShareBasedCompensation
5349000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2328000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1451000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-22000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
274000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6454000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1289000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2889000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
31000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1260000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1345000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58612000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44064000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
89000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
336055000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
143058000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
90181000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
59300000
vera Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
4000000
vera Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
9543000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-241963000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-74215000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
10350000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
672000
vera Proceeds From Short Swing Settlement
ProceedsFromShortSwingSettlement
37000
vera Proceeds From Short Swing Settlement
ProceedsFromShortSwingSettlement
0
vera Proceeds From Issuance Of Common Stock Follow On Offering
ProceedsFromIssuanceOfCommonStockFollowOnOffering
287500000
vera Proceeds From Issuance Of Common Stock Follow On Offering
ProceedsFromIssuanceOfCommonStockFollowOnOffering
115000000
vera Payments Of Stock Issuance Costs On Follow On Offering
PaymentsOfStockIssuanceCostsOnFollowOnOffering
17908000
vera Payments Of Stock Issuance Costs On Follow On Offering
PaymentsOfStockIssuanceCostsOnFollowOnOffering
7256000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
279979000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
108416000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20596000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9863000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45681000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43752000
us-gaap Interest Paid Net
InterestPaidNet
3254000
us-gaap Interest Paid Net
InterestPaidNet
1636000
us-gaap Operating Lease Payments
OperatingLeasePayments
1528000
us-gaap Operating Lease Payments
OperatingLeasePayments
1492000
vera Receivable On Exercise Of Stock Options
ReceivableOnExerciseOfStockOptions
0
vera Receivable On Exercise Of Stock Options
ReceivableOnExerciseOfStockOptions
5000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. ORGANIZATION AND DESCRIPTION OF THE BUSINESS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vera Therapeutics, Inc. (the Company) is a clinical stage biotechnology company focused on developing and commercializing treatments for patients with serious immunological diseases. The Company was incorporated in May 2016 in Delaware. The Company’s headquarters and operations are located in Brisbane, California. The Company operates in one segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Initial Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 13, 2021, the Company’s registration statement on Form S-1 for its initial public offering (the IPO) was declared effective by the Securities and Exchange Commission (the SEC), and the shares of its Class A common stock commenced trading on the Nasdaq Global Select Market on May 14, 2021. The IPO closed on May 18, 2021. Prior to the completion of the IPO, all shares of redeemable convertible preferred stock then outstanding were converted into shares of Class A and Class B common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, the Company devoted substantially all of its resources to its research and development efforts, pre-clinical studies and clinical trials, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. The Company has incurred recurring net operating losses and has not generated positive cash flow from operations since its inception and had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">371.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of June 30, 2024. The Company had cash, cash equivalents and marketable securities of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">384.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as of June 30, 2024. The Company has funded its operations primarily through the issuance of common stock, redeemable convertible preferred stock, debt financing and convertible notes. Management expects to continue to incur losses and negative cash flows from operations for at least the next several years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management believes that the Company’s cash, cash equivalents and marketable securities as of June 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months subsequent to the issuance date of these financial statements. The Company intends to raise additional capital through public or private equity offerings or debt financing or other capital sources, which may include strategic collaborations or other arrangements with third parties in order to achieve its long-term business objectives. If the Company fails to obtain necessary capital when needed on acceptable terms, or at all, it could force the Company to delay, limit, reduce or terminate its product development programs, commercialization efforts or other operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-371200000
CY2024Q2 vera Cash And Cash Equivalents And Marketable Securities
CashAndCashEquivalentsAndMarketableSecurities
384400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Management estimates that affect the reported amounts of assets and liabilities include the accrual of research and development expenses, stock-based compensation expense, determination of incremental borrowing rate for operating leases, the valuation allowance for deferred tax assets, and fair value of marketable and non-marketable securities. The Company evaluates and adjusts its estimates and assumptions on an ongoing basis using historical experience and other factors. Actual results could differ materially from those estimates.</span>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentrations of Credit Risk and Other Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains bank deposits in a federally insured financial institution and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institution holding its cash, cash equivalents, and marketable securities to the extent recorded in the balance sheet. The Company has not experienced any losses to date related to these concentrations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s current and potential future product candidates, uncertainty of market acceptance of the Company’s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers. The Company relies on one supply chain for each of its product candidates. If any of the single source suppliers in any of the supply chains fails to satisfy the Company’s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect operating results.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s product candidates require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory authorities prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed, or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</span>
CY2024Q2 vera Prepaid Clinical Trial Costs
PrepaidClinicalTrialCosts
4371000
CY2023Q4 vera Prepaid Clinical Trial Costs
PrepaidClinicalTrialCosts
5273000
CY2024Q2 us-gaap Interest Receivable
InterestReceivable
1960000
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
512000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
1247000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
597000
CY2024Q2 vera Prepaid Drug Manufacturing Costs
PrepaidDrugManufacturingCosts
873000
CY2023Q4 vera Prepaid Drug Manufacturing Costs
PrepaidDrugManufacturingCosts
2578000
CY2024Q2 vera Prepaid Commercial Costs
PrepaidCommercialCosts
574000
CY2023Q4 vera Prepaid Commercial Costs
PrepaidCommercialCosts
789000
CY2024Q2 vera Prepaid Software Costs
PrepaidSoftwareCosts
393000
CY2023Q4 vera Prepaid Software Costs
PrepaidSoftwareCosts
237000
CY2024Q2 us-gaap Prepaid Rent
PrepaidRent
274000
CY2023Q4 us-gaap Prepaid Rent
PrepaidRent
257000
CY2024Q2 vera Prepaid Professionals Services
PrepaidProfessionalsServices
239000
CY2023Q4 vera Prepaid Professionals Services
PrepaidProfessionalsServices
198000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
429000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
866000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10360000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11307000
CY2024Q2 vera Accrued Clinical And Drug Manufacturing Expenses
AccruedClinicalAndDrugManufacturingExpenses
8131000
CY2023Q4 vera Accrued Clinical And Drug Manufacturing Expenses
AccruedClinicalAndDrugManufacturingExpenses
2213000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2582000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3932000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
820000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
678000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11638000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8749000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
363300000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
115000000
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
381165000
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
46000
vera Available For Sale Debt Securities Gross Unrealized Loss1
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1
496000
CY2024Q2 vera Cash Equivalent And Marketable Securities
CashEquivalentAndMarketableSecurities
380715000
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
25085000
CY2024Q2 us-gaap Marketable Securities
MarketableSecurities
359302000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
159434000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
271000
CY2023 vera Available For Sale Debt Securities Gross Unrealized Loss1
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1
20000
CY2023Q4 vera Cash Equivalent And Marketable Securities
CashEquivalentAndMarketableSecurities
159685000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
45681000
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
115035000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
278948000
CY2024Q2 vera Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
80354000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
359302000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
644000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
644000
us-gaap Operating Lease Cost
OperatingLeaseCost
1289000
us-gaap Operating Lease Cost
OperatingLeaseCost
1289000
CY2024Q2 us-gaap Sublease Income
SubleaseIncome
482000
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
482000
us-gaap Sublease Income
SubleaseIncome
964000
us-gaap Sublease Income
SubleaseIncome
964000
CY2024Q2 us-gaap Lease Cost
LeaseCost
162000
CY2023Q2 us-gaap Lease Cost
LeaseCost
162000
us-gaap Lease Cost
LeaseCost
325000
us-gaap Lease Cost
LeaseCost
325000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1493000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1880000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
0
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3373000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
802000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2571000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2116000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
455000
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
979000
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
1496000
CY2024Q2 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
2475000
CY2024Q2 vera Operating Leases Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumSubleaseRentals
3100000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y1M6D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2024Q2 us-gaap Notes Payable
NotesPayable
50000000
CY2023Q4 us-gaap Notes Payable
NotesPayable
50000000
CY2024Q2 vera Accrued Exit Fee Net Of Unamortized Issuance Costs
AccruedExitFeeNetOfUnamortizedIssuanceCosts
263000
CY2023Q4 vera Accrued Exit Fee Net Of Unamortized Issuance Costs
AccruedExitFeeNetOfUnamortizedIssuanceCosts
123000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
50263000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
49877000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
50000000
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2024Q2 vera Maximum Aggregate Offering Price Of Securities Under Shelf Registration
MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
400000000
CY2024Q2 vera Maximum Aggregate Offering Price Of Securities Under Shelf Registration
MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
400000000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
10600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
31200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
80989
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4873000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2682000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8997000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5349000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4873000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2682000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8997000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5349000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.719
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.728
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.802
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.805
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.677
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.728
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.795
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.805
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.043
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.046
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.034
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.038
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.038
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.046
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.034
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.04
CY2024Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
14000000
CY2023Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
18000000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
152000000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
127000000
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6742406
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6048562
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6742406
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6048562
vera Proceeds From Short Swing Profits
ProceedsFromShortSwingProfits
36620000
vera Proceeds From Disgorgement Representing Short Swing Profits
ProceedsFromDisgorgementRepresentingShortSwingProfits
36620000

Files In Submission

Name View Source Status
0000950170-24-094108-index-headers.html Edgar Link pending
0000950170-24-094108-index.html Edgar Link pending
0000950170-24-094108.txt Edgar Link pending
0000950170-24-094108-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img129449286_0.jpg Edgar Link pending
img129449286_1.jpg Edgar Link pending
img129449286_2.jpg Edgar Link pending
img129449286_3.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vera-20240630.htm Edgar Link pending
vera-20240630.xsd Edgar Link pending
vera-ex10_1.htm Edgar Link pending
vera-ex31_1.htm Edgar Link pending
vera-ex31_2.htm Edgar Link pending
vera-ex32_1.htm Edgar Link pending
vera-ex32_2.htm Edgar Link pending
vera-20240630_htm.xml Edgar Link completed